Published in final edited form as:

ChemMedChem. 2019 July 17; 14(14): 1321–1324. doi:10.1002/cmdc.201900341.

Small-Molecule Activators of Glucose-6-phosphate Dehydrogenase (G6PD) Bridging the Dimer Interface

Andrew G. Raub^{a,b}, Sunhee Hwang^a, Naoki Horikoshi^{c,d,e}, Anna D. Cunningham^{a,f}, Simin Rahighi^{d,e,g}, Soichi Wakatsuki^{d,e}, Daria Mochly-Rosen^a

^[a]Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, CA 94305 (USA)

^[b]Department of Chemistry, Stanford University, Stanford, CA 94305 (USA)

^[c]Life Science Center for Survival Dynamics, Tsukuba Advanced Research Alliance, University of Tsukuba, Ibaraki 305-8575 (Japan)

^[d]Department of Structural Biology, Stanford University School of Medicine, Stanford, CA 94305 (USA)

^[e]Biosciences Division, SLAC National Laboratory, Menlo Park, CA 94025 (USA)

^[f]Freenome Inc., 259 E. Grand Ave., South San Francisco, CA 94080 (USA)

^[g]Chapman University School of Pharmacy (CUSP), Irvine, CA 92618 (USA)

Abstract

We recently identified AG1, a small-molecule activator that functions by promoting oligomerization of glucose-6-phosphate dehydrogenase (G6PD) to the catalytically competent forms. Biochemical experiments indicate that the activation of G6PD by the original hit molecule (AG1) is noncovalent and that one C_2 -symmetric region of the G6PD homodimer is important for ligand function. Consequently, the disulfide in AG1 is not required for activation of G6PD, and a number of analogues were prepared without this reactive moiety. Our study supports a mechanism of action whereby AG1 bridges the dimer interface at the structural nicotinamide adenine dinucleotide phosphate (NADP⁺) binding sites of two interacting G6PD monomers. Small molecules that promote G6PD oligomerization have the potential to provide a first-in-class treatment for G6PD deficiency. This general strategy could be applied to other enzyme deficiencies in which control of oligomerization can enhance enzymatic activity and/or stability.

mochly@stanford.edu.

Author Contributions

A.R. Conceptualization: Supporting; Data curation: Lead; Investigation: Lead; Methodology: Supporting; Writing - Original Draft: Lead; Writing - Review & Editing: Lead S. H. Data curation: Supporting; Investigation: Supporting; Methodology: Supporting; Writing - Review & Editing: Supporting N.H. Data curation: Supporting; Investigation: Supporting; Writing - Review & Editing: Supporting A. C. Data curation: Supporting; Methodology: Supporting; Writing - Review & Editing: Supporting S.R. Methodology: Supporting; Writing - Review & Editing: Supporting S.W. Conceptualization: Supporting; Investigation: Supporting; Methodology: Supporting; Supervision: Supporting; Writing - Review & Editing: Supporting D.M. Conceptualization: Supporting; Funding acquisition: Lead; Investigation: Supporting; Resources: Lead; Supervision: Lead; Writing - Review & Editing: Supporting.

Supporting information and the ORCID identification number(s) for the author(s) of this article can be found under: <https://doi.org/10.1002/cmdc.201900341>.

Conflict of interest

The authors declare no conflict of interest.

Graphical Abstract

Coming together: A novel class of small-molecule glucose-6-phosphate dehydrogenase (G6PD) activators is described. Structural studies support a mechanism of action whereby the small molecules bind across the G6PD dimer interface to promote oligomerization to the more catalytically competent enzyme state(s).

Keywords

bivalent ligands; enzyme catalysis; glucose-6-phosphate dehydrogenase; protein-protein interactions; small-molecule activators

Protein-protein interactions (PPIs) underpin the vast signaling networks essential for cellular functions. The interactome, estimated at 650 000,^[1] is an area ripe for modulating disease pathogenesis.^[2] Beyond signaling events, the interactome includes quaternary structural interactions between proteins, which regulate enzyme stability, activity, and function.^[3] However, targeting PPIs with small molecules has long been considered a challenging area for drug discovery largely outside the realm of the druggable genome.^[4] Yet, a number of methods such as fragment-based drug discovery (FBDD) and rational peptide design have produced leads with translational potential.^[5,6] Efforts focused on modulating PPIs have almost entirely centered around the inhibition of these interactions,^[7] but a number of natural products and designed ligands derive clinical utility from promoting the interaction of two or more proteins.^[8]

G6PD, an ancient metabolic enzyme present in eukaryotes and prokaryotes, catalyzes the first step of the pentose phosphate pathway (PPP).^[9] Products of the PPP are important for the biosynthesis of nucleotides and fatty acids. NADPH is essential for generating reduced glutathione, the cell's primary defense against electrophiles and oxidants. Despite the critical role G6PD plays in the cell, G6PD deficiency is the second most common human enzymopathy; more than 160 single-nucleotide substitutions that alter enzymatic activity and/or stability have been identified in humans.^[10] Missense mutations result in a variety of clinical phenotypes depending on the nature and location of the mutation.^[11] For example, mutations affecting the homodimer interface of G6PD are particularly pathogenic, as only the homodimeric and homotetrameric oligomers of G6PD are stable and active in vivo.^[12] G6PD is the only enzyme known to have evolved a second NADP⁺ binding site, close to the dimer interface; this second so-called structural site is essential for maintaining the activity, stability, and oligomeric state of the enzyme.^[13] Mutations that negatively impact binding of NADP⁺ to the structural site also result in pathogenesis.

Despite the prevalence of G6PD deficiency, commonly resulting in mild to severe and chronic hemolytic anemia, no therapies currently exist. Previously, we described a small-

molecule activator (Alda-1) of aldehyde dehydrogenase 2 (ALDH2),^[14] which activates the most common single-point mutation in humans, ALDH2*2 by robustly correcting its structural defect.^[15] Enzyme activation, like PPI stabilization, is a nascent pharmacological modality in drug discovery, and identifying novel mechanisms to enhance enzyme function is of significant clinical interest.^[16,17] Encouraged by the discovery of Alda-1, we set out to identify small molecules that enhance the activity of pathogenic mutants of G6PD. A biochemical screen was conducted using a common, pathogenic mutant (Canton G6PD, R459L) endemic to Southeast Asia.^[18] A small-molecule activator of several pathogenic forms of G6PD (AG1 (**2**), Scheme 1) was identified from the screen, and a detailed mechanistic understanding of AG1 was required to further our translational objectives.^[19]

First, we found that analogues (e.g., **3**, Scheme 1) prepared using the pharmacophore of the structure provided by the vendor (**1**) were inactive. We reasoned that the original molecule **1** can undergo oxidation to the disulfide under ambient conditions.^[20] When the dimeric molecule AG1 was independently synthesized and purified, it recapitulated the activation originally observed in the high-throughput screen: 20 and 60% increases in the activity of the wild-type and the Canton mutant, respectively. Biochemical experiments indicated that AG1 activates G6PD in a noncovalent fashion (Supporting Information (SI) Figure S1).

G6PD is active as a dimer or tetramer, but not as a monomer.^[21] Considering that the active ligand is a dimer, which promotes oligomerization in a dose-dependent manner, it seemed possible that AG1 spans part of the C_2 -symmetric dimer interface, directly stabilizing the G6PD homodimer. Examination of the two C_2 -symmetric regions at the dimer interface identified one region that can accommodate the pharmacophore of AG1 (Figure 1 A). In the G6PD structure, the pyridinium ring of the structural NADP⁺ forms a π -stack with Trp509 (W509), which is approximately 5 Å from Asp421 (D421). This feature is repeated on the other monomer, with the two Asp421 residues separated by 7 Å. AG1 was docked into this region after removing the unstructured C-terminal residues in the enzyme up to Trp509 (Figure 1 B). Docking of the ligand between the structural NADP⁺ sites reveals an asymmetric pose (Figure 1 B), which places the two amines in AG1 near Asp421 and Glu419 (E419). A new π -stack of the indole in AG1 is formed with the pyridinium ring of the structural NADP⁺.

To determine if Asp421 and Glu419 participate in AG1 binding, a mutational analysis around the two C_2 points of symmetry was initiated in the Canton G6PD mutant enzyme (Figure 2). First, residues that could complement the ligand at the C_2 -symmetric site distal from the structural NADP⁺ were mutated to serve as a control (Figure 2A, bottom). Two anionic residues, Asp228 and Glu347, were mutated to alanine (Ala, A). Additionally, a hydrophobic pocket in this region near Gly222 (G222), which could accommodate an indole ring, was mutated to an alanine to occlude this space. When AG1 was docked to this region of the enzyme, none of the poses generated were favorable relative to the conformation of AG1 docked to the structural NADP⁺ sites. Anionic residues at the predicted site between the structural NADP⁺ (Figure 2A, top), Asp421 (red), Glu419 (blue), and the double mutant (purple) were mutated to alanine. To assess the effect of the mutations, the AC₅₀ (concentration at half-maximal activation) of AG1 in the relevant mutated enzyme was normalized to the AC₅₀ of AG1 in unmutated Canton G6PD (Figure 2B); values greater than

1 indicate that the given mutation attenuated the activation by AG1. Analysis of these mutant enzymes indicated that none of the structural changes affected the efficacy of the ligand on the site distal to the structural NADP⁺ within error. In contrast, mutations at the dimer interface between the structural NADP⁺, where AG1 was predicted to bind, significantly perturbed the AC₅₀ (D421A and E419A/D421A).

In addition to generating mutations, which were predicted to negatively impact the function of AG1, we predicted that one mutation may enhance the activation and/or binding of AG1. In the crystal structure of Canton G6PD, Trp509 forms a π -stack with the structural NADP⁺ (Figure 1 A). Previous studies demonstrated that the presence of the structural NADP⁺ is crucial for maintaining the activity and stability of the enzyme.^[22] We therefore reasoned that removing Trp509 and replacing it with alanine would impair G6PD function, but that AG1 should have a greater compensatory effect in this mutation. Additionally, because this Trp appears to compete with AG1 for binding to the structural NADP⁺ site, we expected that mutating Trp509 should not affect the AC₅₀ negatively or possibly lower the AC₅₀. The ligand, which had an A_{max} value of 1.2-fold in wild-type G6PD and an AC₅₀ = 4.2 μ M, activated the Trp509Ala mutant enzyme 1.7-fold with an AC₅₀ = 0.8 μ M (SI Figure S2).

Given these results, we reasoned that the disulfide is not required for activation and could be replaced with non-reactive linkers (Table 1). The preferred method for synthesis of these analogues was via Fukuyama amine synthesis,^[23] which was superior in all cases examined to the initial route of amide formation and reduction. As expected, from analysis of the dimer interface and the pharmacophore, shorter linkers—analogue **6** (four-carbon linker) and **7** (five-carbon linker)—did not function as activators, but in fact inhibited enzyme function. Simply replacing one atom in **7** with a sulfur atom resulted in conversion of an inhibitor to a dose-dependent activator (**8**). Analogues **5** (three-carbon linker), **9** (six-carbon linker), **10** (seven-carbon linker) and **11** (eight-carbon linker) modestly activated the enzyme without prominent sigmoidal dose-response curves. Analogues **8**, **2**, **12** (nine-carbon linker), **13** (ten-carbon linker), and **15** (twelve-carbon linker) all exhibited approximately equal activation (1.6-fold) and sigmoidal, dose-dependent activation. Analogue **12** was only two-fold less potent than the original disulfide-containing analogue **2**. Similarly to AG1 (**2**), analogues **10**, **12**, and **13** increased the oligomerization of the enzyme (SI Figure S3).

Pharmacological modulation of PPIs, a promising area of drug discovery, remains elusive. Moreover, ligands capable of stabilizing PPIs are rarer still. As discussed, many pathological G6PD mutations have been identified in humans, and AG1 promotes the activation of at least several pathogenic mutants. Our current study sheds light on the mechanism by which such a poly-genotypic activator of G6PD acts. This novel class of molecules was originally discovered due to the correct identification of the active species (AG1, **2**) in samples of the primary thiol **1**. Mutational analyses and biochemical experiments support a mechanism of action whereby AG1 promotes G6PD dimerization by bridging two structural NADP⁺ molecules. Efforts to optimize these G6PD activators and evaluate their translational potential as a first-in-class treatment for G6PD deficiency are ongoing. Given the omnipresence of PPI regulation in both cellular signaling events and enzyme activity/stability, we anticipate that small-molecule stabilization of PPIs will be increasingly valuable in drug discovery.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

The authors thank Dr. Steven Schow (Adjunct Professor; Chemical and Systems Biology, Stanford University), Dr. Daniel A. Erlanson (Carmot Therapeutics, Inc.) and Dr. Mark Smith (Medicinal Chemistry Knowledge Center, ChEM-H Stanford University) for their consultations and support of this work. This project was funded by US National Institutes of Health (NIH) grant HD084422 to D.M.-R., seed funds from the NIH National Center for Advancing Translational Science Clinical and Translational Science Award (UL1TR001085), the Stanford Child Health Research Institute Transdisciplinary Initiatives Program (TIP) grant, SPARK (a translational research program at Stanford), and Weston Havens Foundation to S.H. and A.G.R.

References

- [1]. Stumpf MPH, Thome T, de Silva E, Stewart R, An HJ, Lappe M, Wiuf C, Proc. Natl. Acad. Sci. USA 2008, 105, 6959–6964. [PubMed: 18474861]
- [2]. Bosch J, Drug Discovery Today Technol. 2017, 24, 3–9.
- [3]. Matthews JM, Sunde M in Protein Dimerization and Oligomerization in Biology Vol. 747 (Eds.: Matthews JM), Springer, New York, 2012, pp. 1–18.
- [4]. Hopkins AL, Groom CR, Nat. Rev. Drug Discovery 2002, 1, 727–730. [PubMed: 12209152]
- [5]. Wang F, Fesik SW in Fragment-based Drug Discovery: Lessons and Outlook, Vol. 67 (Eds.: Erlanson DA, Jahnke W), Wiley-VCH, Weinheim, 2016, pp. 371–390.
- [6]. Cunningham AD, Qvit N, Mochly-Rosen D, Curr. Opin. Struct. Biol 2017, 44, 59–66. [PubMed: 28063303]
- [7]. Thiel P, Kaiser M, Ottmann C, Angew. Chem. Int. Ed 2012, 57, 2012–2018; Angew. Chem. 2012, 124, 2052–2059.
- [8]. Andrei SA, Sijbesma E, Hann M, Davis J, O'Mahony G, Perry MWD, Karawajczyk A, Eickhoff J, Brunsveld L, Doveston RG, Milroy LG, Ottmann C, Expert Opin. Drug Discovery 2017, 72, 9250940.
- [9]. Cappellini MD, Fiorelli G, Lancet 2008, 371, 64–74. [PubMed: 18177777]
- [10]. Cunningham AD, Hwang S, Mochly-Rosen D, Clin. Perinatol 2016, 43, 341–354. [PubMed: 27235212]
- [11]. Cunningham AD, Colavin A, Huang KC, Mochly-Rosen D, Cell Rep. 2017, 18, 2592–2599. [PubMed: 28297664]
- [12]. Cunningham AD, Mochly-Rosen D, Matters 2017, DOI: 10.19185/matters.201705000008.
- [13]. Au SW, Gover S, Lam VM, Adams MJ, Structure 2000, 8, 293–303. [PubMed: 10745013]
- [14]. Chen C-H, Budas GR, Churchill EN, Disatnik MH, Hurley TD, Mochly-Rosen D, Science 2008, 321, 1493–1495. [PubMed: 18787169]
- [15]. Perez-Miller S, Younus H, Vanam R, Chen C-H, Mochly-Rosen D, Hurley TD, Nat. Struct. Mol. Biol 2010, 17, 159–164. [PubMed: 20062057]
- [16]. Zorn JA, Wells JA, Nat. Chem. Biol 2010, 6, 179–188. [PubMed: 20154666]
- [17]. Darby JF, Landström J, Roth C, He Y, Davies GJ, Hubbard RE, Angew. Chem. Int. Ed 2014, 53, 13419–13423; Angew. Chem. 2014, 126, 13637–13641.
- [18]. Jiang W, Yu G, Liu P, Geng Q, Chen L, Lin Q, Ren X, Ye W, He Y, Guo V, Duan S, Wen J, Li H, Qi Y, Jiang C, Zheng Y, Liu C, Si E, Zhang Q, Tian Q, Du C, Hum. Genet 2006, 119, 463–478. [PubMed: 16607506]
- [19]. Hwang S, Mruk K, Rahighi S, Raub AG, Chen C-H, Dorn LE, Hori-koshi N, Wakatsuki S, Chen JK, Mochly-Rosen D, Nat. Commun 2018, 9, 4045. [PubMed: 30279493]
- [20]. Hebeisen P, Kuhn B, Kohler P, Gubler M, Huber W, Kitas E, Schott B, Benz J, Joseph C, Ruf A, Bioorg. Med. Chem. Lett 2008, 18, 4708–4712. [PubMed: 18650089]

- [21]. Bonsignore A, Cancedda R, Lorenzoni I, Cosulich ME, De Flora A, Bio-chem. Biophys. Res. Commun 1971, 43, 94–101.
- [22]. Cameron WD, Bui CV, Hutchinson A, Loppnau P, Gräslund S, Rocheleau JV, Nat. Methods 2016, 13, 352–358. [PubMed: 26878383]
- [23]. Fukuyama T, Jow C-K, Mui C, Tetrahedron Lett. 1995, 36, 6373–6374.

Scheme 1.

Analogues (**3**) developed to mimic the primary thiol in **1** are inactive, but compounds (**4**) designed from the pharmacophore of **2** activate G6PD.

Figure 1.

Residues expected to interact favorably with the pharmacophore of AGI (PDB ID: 1QKI).

A) The dimer interface of Canton G6PD located between the structural NADP⁺ (black, designated as NAP-800) with monomers shaded in dark and light grey. B) AG1 (teal) docked to the dimer interface using the Glide program in the Schrödinger software suite.

Figure 2.

Mutagenesis of residues expected to interact favorably with the pharmacophore of AG1 about both C_2 -symmetric dimer interfaces suggests the region between the structural $NADP^+$ is important for ligand binding (PDB ID: 1QKI). A) Surface model of G6PD homodimer colored with the mutated residues (color coded), AG1 docked in teal (C terminus deleted to residue 501), and the cofactors in black (catalytic $NADP^+$ (I), G6P (II), structural $NADP^+$ (III)). B) Mutations of anionic residues between the structural $NADP^+$ attenuate the activity of AG1, but do not have any significant effect on the opposite dimer interface (* $p = 0.0075$, *** $p < 0.0001$).

Table 1.

Impact of linker on the activation of Canton G6PD.

Compd ^[a]	Linker	AC ₅₀ [μM] ^[a]	A _{max} [%] ^[a]
5		— ^[b]	135 ^[b]
6		— ^[c]	— ^[c]
7		— ^[c]	— ^[c]
8		33	155
9		— ^[b]	119 ^[b]
2		3.3	160
10		— ^[b]	123 ^[b]
11		— ^[b]	130 ^[b]
12		7.7	160
13		15	159
14		— ^[b]	104 ^[b]
15		12	146

^[a] AC₅₀ values were obtained by titration of activators in a biochemical assay of Canton G6PD activity with substrate concentrations close to physiologically relevant conditions (95% confidence intervals of AC₅₀ values are available in the SI).

^[b] Significant dose–response curves are not obtained with these compounds, and activation is instead reported at 50 μM.

^[c] Compounds were found to inhibit the enzyme in a dose-dependent manner (see SI).